<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878590</url>
  </required_header>
  <id_info>
    <org_study_id>INN-C003</org_study_id>
    <nct_id>NCT02878590</nct_id>
  </id_info>
  <brief_title>Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA)</brief_title>
  <official_title>Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnoMed Healthscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RVW Clinical Consulting</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InnoMed Healthscience Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, open label study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-randomized, open label, single-center clinical study for
      the BONGO NASAL device for the treatment of obstructive sleep apnea. The study consists of
      two in laboratory polysomnographic studies and a one two week in home period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea Hypopnea Index</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>BONGO DEVICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the intervention of the Bongo device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BONGO DEVICE</intervention_name>
    <description>A device to be used for the treatment of mild to moderate obstructive sleep apnea</description>
    <arm_group_label>BONGO DEVICE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Capacity and willingness to sign informed consent

               -  ≥ 21 years of age

               -  Diagnosis of mild to moderate OSA (AHI ≥ 5 and AHI ≤ 30) within 12 months of the
                  screening visit with the 3% hypopnea criteria

               -  Able to tolerate using the device during a day time trial/acclimation

               -  Are currently using CPAP or have been prescribed CPAP and are considered CPAP
                  non-adherent (as per either their CPAP data card and/or verbal confirmation of a
                  diagnosis and unwillingness to use CPAP)

        Exclusion Criteria:

          -  • Nasal deformities

               -  Severe nasal allergies

               -  Rhinitis or moderate nasal congestion, acute upper respiratory (including nasal,
                  sinus or middle ear) inflammation or infection, or perforation of the ear drum

               -  Co-morbid sleep disorders

               -  Currently on a hypnotic for insomnia (who have had insomnia for more than a
                  month and take a hypnotic on a daily basis and/or transient insomnia being
                  treated)

               -  Uncontrolled or serious illness, including but not limited to: severe breathing
                  disorders including hypercapnic respiratory failure, respiratory muscle
                  weakness, bullous lung disease (as seen in some types of emphysema), bypassed
                  upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease
                  (including heart failure); or pathologically low blood pressure.

               -  Full Face Mask user

               -  Mouth breather

               -  Pregnant (Female subjects of child bearing age will be asked if they are and/or
                  planning on becoming pregnant during the study; acceptable methods of birth
                  control include birth control pills and barrier method)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jerrold kram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Center for Sleep Disorders</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>javier collazo</last_name>
    <phone>954.773.9656</phone>
    <email>javier@innomedtechnologies.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>robyn woidtke</last_name>
    <phone>5107280828</phone>
    <email>robyn.woidtke@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Center for Sleep Disorders</name>
      <address>
        <city>Alameda</city>
        <state>California</state>
        <zip>94501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jerrold kram</last_name>
      <phone>510-263-3300</phone>
      <email>robyn.woidtke@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>August 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
